These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 688233)

  • 1. Pharmacokinetics of fluorouracil in humans.
    MacMillan WE; Wolberg WH; Welling PG
    Cancer Res; 1978 Oct; 38(10):3479-82. PubMed ID: 688233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition of 5-fluorouracil after intravenous bolus doses of a commercial formulation to cancer patients.
    Sitar DS; Shaw DH; Thirlwell MP; Ruedy JR
    Cancer Res; 1977 Nov; 37(11):3981-4. PubMed ID: 908036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
    Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
    Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
    Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
    Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
    Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
    Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of 5-fluorouracil after short systemic infusion: plasma level at the end of the distribution phase as an indicator of the total area under the plasma concentration-time curve.
    Port RE; Edler L; Herrmann R; Feldmann U
    Ther Drug Monit; 1991 Mar; 13(2):96-102. PubMed ID: 2053130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients.
    Wagner JG; Gyves JW; Stetson PL; Walker-Andrews SC; Wollner IS; Cochran MK; Ensminger WD
    Cancer Res; 1986 Mar; 46(3):1499-506. PubMed ID: 3943107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered plasma kinetics of 5-FU at high dosage in rat and man.
    Schwartz PM; Turek PJ; Hyde CM; Cadman EC; Handschumacher RE
    Cancer Treat Rep; 1985 Jan; 69(1):133-6. PubMed ID: 3967255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial.
    Kirkwood JM; Ensminger W; Rosowsky A; Papathanasopoulos N; Frei E
    Cancer Res; 1980 Jan; 40(1):107-13. PubMed ID: 7349890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin.
    Choi YH; Lee AK; Bae SK; Kim SO; Lee MG
    Biopharm Drug Dispos; 2005 Apr; 26(3):93-8. PubMed ID: 15674819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy of extensive digestive cancers with 5-fluorouracil: relation between the clinical response and plasma clearance of the drug].
    Seitz JF; Cano JP; Rigault JP; Aubert C; Carcassonne Y
    Gastroenterol Clin Biol; 1983 Apr; 7(4):374-80. PubMed ID: 6873549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
    Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile.
    Heggie GD; Sommadossi JP; Cross DS; Huster WJ; Diasio RB
    Cancer Res; 1987 Apr; 47(8):2203-6. PubMed ID: 3829006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects.
    Hunt TL; Gallagher SC; Cullen MT; Shah AK
    J Clin Pharmacol; 2005 May; 45(5):589-96. PubMed ID: 15831783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.
    Zia-Amirhosseini P; Hurd DD; Salfi M; Cheah TC; Aycock J; Cesano A
    Pharmacotherapy; 2007 Oct; 27(10):1353-60. PubMed ID: 17896890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of high and moderate intravenous doses of methotrexate.
    Awidi A; al-Turk A; Madanat F; Othman S; Shaheen O
    Res Commun Chem Pathol Pharmacol; 1988 Mar; 59(3):411-4. PubMed ID: 3363225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule.
    van Groeningen CJ; Pinedo HM; Heddes J; Kok RM; de Jong AP; Wattel E; Peters GJ; Lankelma J
    Cancer Res; 1988 Dec; 48(23):6956-61. PubMed ID: 3180104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.